New weapon to curb smoking: No more excuses to delay treatment

Archives of Internal Medicine

Volumn 166, Issue 15, 2006, Pages 1547-1550

  Johnson, Bankole A ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; CANNABINOID 1 RECEPTOR; CYTISINE; FLUOXETINE; NICOTINE; NICOTINE GUM; NICOTINE PATCH; NICOTINE VACCINE; NORTRIPTYLINE; RIMONABANT; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE; UNCLASSIFIED DRUG; VACCINE; VARENICLINE;

DRUG EFFECT; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; FOLLOW UP; HEART INFARCTION; HUMAN; HYPERTENSION; INSOMNIA; MEDICAL RESEARCH; NAUSEA; NICOTINE REPLACEMENT THERAPY; PALATABILITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; SEDATION; SEIZURE; SIDE EFFECT; SMOKING CESSATION; URINE RETENTION; WITHDRAWAL SYNDROME; XEROSTOMIA;

BENZAZEPINES; FRUCTOSE; HUMANS; NEUROPROTECTIVE AGENTS; NICOTINE; NICOTINIC AGONISTS; NICOTINIC ANTAGONISTS; QUINOXALINES; SMOKING CESSATION; TOBACCO USE DISORDER;

EID: 33747192842     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.166.15.1547     Document Type: Editorial

References (23)

1. Graul AI, Prous JR. Executive summary: nicotine addiction. Drugs Today (Barc). 2005;41:419-425.
2. Berrettini WH, Lerman CE. Pharmacotherapy and pharmacogenetics of nicotine dependence. Am J Psychiatry. 2005;162:1441-1451.
3. Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2004;(3):CD000146.
4. Slotkin TA. Fetal nicotine or cocaine exposure: which one is worse? J Pharmacol Exp Ther. 1998;285:931-945.
5. PDR. Physicians' Desk Reference. 51st ed. Montvale, NJ: Medical Economics Co, Inc; 1997.
6. Hajek P, West R, Foulds J, Nilsson F, Burrows S, Meadow A. Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. Arch Intern Med. 1999;159:2033-2038.
7. West R, Hajek P, Nilsson F, Foulds J, May S, Meadows A. Individual differences in preferences for and responses to four nicotine replacement products. Psychopharmacology (Berl). 2001;153:225-230.
8. West R, Hajek P, Foulds J, Nilsson F, May S, Meadows A. A comparison of the abuse liability and dependence potential of nicotine patch, gum, spray and inhaler. Psychopharmacology (Berl). 2000;149:198-202.
9. McNeill A, Foulds J, Bates C. Regulation of nicotine replacement therapies (NRT): a critique of current practice. Addiction. 2001;96:1757-1768.
10. Hughes J, Stead L, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2004;(4):CD000031.
11. Hurt RD, Sachs DP, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med. 1997;337:1195-1202.
12. Jorenby DE, Leischow SJ, Nides MA, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med. 1999;340:685-691.
13. Prochazka AV. New developments in smoking cessation. Chest. 2000;117:169S-175S.
14. Nides M, Oncken C, Gonzales D, et al; Varenicline Study Group. Smoking cessation with varenicline, a selective α4β2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with one-year follow-up. Arch Intern Med. 2006;166:1561-1568.
15. Oncken C, Gonzales D, Nides M, et al; Varenicline Study Group. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med. 2006;166:1571-1577.
16. Etter J-F. Cytisine for smoking cessation: a literature review and a meta-analysis. Arch Intern Med. 2006;166:1553-1559.
17. Johnson BA. Topiramate-induced neuromodulation of cortico-mesolimbic dopamine function: a new vista for the treatment of comorbid alcohol and nicotine dependence? Addict Behav. 2004;29:1465-1479.
18. Johnson BA, Ait-Daoud N, Akhtar FZ, Javors MA. Use of oral topiramate to promote smoking abstinence among alcohol-dependent smokers: a randomized controlled trial. Arch Intern Med. 2005;165:1600-1605.
19. Johnson BA, Ait-Daoud N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet. 2003;361:1677-1685.
20. Anthenelli RM, Blom TJ, McElroy SL, Keck PE Jr. A double-blind, placebo-controlled trial of topiramate as an aid to smoking cessation. Poster presented at: 12th Annual Meeting of the Society for Research on Nicotine and Tobacco; February 15-18, 2006; Orlando, Fla.
21. Lindblom N, de Villiers SH, Semenova S, et al. Active immunisation against nicotine blocks the reward facilitating effects of nicotine and partially prevents nicotine withdrawal in the rat as measured by dopamine output in the nucleus accumbens, brain reward thresholds and somatic signs. Naunyn Schmiedebergs Arch Pharmacol. 2005;372:182-194.
22. Hatsukami DK, Rennard S, Jorenby D, et al. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin Pharmacol Ther. 2005;78:456-467.
23. Fagerström K, Balfour DJK. Neuropharmacology and potential efficacy of new treatments for tobacco dependence. Expert Opin Investig Drugs. 2006;15:107-116.